Our strategic goals are focused on investment initiatives in the Digital, IT and Healthcare sectors.
Argus Worldwide Corp. is focused on target investments that bring to the company ‘NEW AGE’ technologies and processes.
Our strategy makes use of knowledge based investments that takes advantage of our unique expertise in the IT and Healthcare sectors. Ultimately, by targeting and building out within the Argus umbrella a management team well trained and experienced in the business segments we serve, our company will be better positioned to achieve its outer limits of growth and development in the years ahead.
At the end of the day, our success will depend on diligent investments, the management skillset we employ to exploit our investments, and how well we can execute and deliver on our corporate goals and objectives to ensure sound growth in revenues and profitability over time.
In a Digital World
On December 10, 2016, the Company entered into a definitive Purchase Agreement to acquire Cyber Junky Sp.z o.o.. an early stage ‘Internet of things’ business based in Warsaw Poland. The object of the CJ business is to design, develop and operate a state of the art Internet platform for desk top computer or mobile use which will serve as a one stop user friendly aggregator of a broad range of internet based applications. Whether the user wishes to chat with friends, surf the Net, shop on line, pay a bill, make a date, or plan for the next vacation, we believe that the Cyber Junky platform will fast become one of the most favorite ways of getting the task done.
At Argus Worldwide, we believe that concomitantly with our acquisition of BioPharmcor BV and its wholly owned subsidiaries in Poland and Canada, we are participating in the dawning of a new age in the pharmaceutical business, one in which generic drugs, in concert with advanced technologies and custom tailored therapies, will form the arsenal for Big Pharma.
The Company’s BioPharmcor unit has recently completed a development program to formulate a generic tadalafil drug product to treat the symptoms of Erectile Dysfunction (ED) and Benign Prostatic Hyperplasia (BPH) in men. The Company is now preparing for an intensive period of human clinical trials well into fiscal 2018. The clinical trials are essential to demonstrate the bioequivalence of the BioPharmcor generic tadalafil drug against the marketed name brand patented product, to support submissions for market approval initially in the EU and Canada.It is estimated that the market for ED drug remedies is approximately $4.5 billion worldwide.